Trial site
City of Hope Seacliff
Huntington Beach, California 92648, United StatesNot linked to an institution yet
- 16running trials
- 2closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 35 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Not yet recruiting2 trials
- Completed1 trial
- Withdrawn1 trial
- Lead sponsor
- City of Hope Medical Center5 trials
- National Cancer Institute (NCI)5 trials
- Janssen Research & Development, LLC2 trials
- NRG Oncology2 trials
- Boehringer Ingelheim1 trial
- and 3 more
Running trials
Recruiting
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
NCT07595874· Phase 2· City of Hope Medical Center· Source
Contact: Pashtoon M. Kasi
Recruiting
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
NCT07288034· Phase 2· City of Hope Medical Center· Source
Contact: Ravi Salgia
Recruiting
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
NCT07225738· City of Hope Medical Center· Source
Contact: Richard T. Lee
Recruiting
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT07125729· City of Hope Medical Center· Source
Contact: Marwan G. Fakih
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
NCT06524973· City of Hope Medical Center· Source
Contact: Vincent Chung, MD
Active, not recruiting
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352· Phase 2· SWOG Cancer Research Network· Source
Contact: Alexey V. Danilov (principal investigator)
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: Alex F. Herrera (principal investigator)
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275· Phase 2/3· National Cancer Institute (NCI)· Source
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· Phase 3· National Cancer Institute (NCI)· Source
Contact: Alexey V. Danilov (principal investigator)
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Mihae Song (principal investigator)
Active, not recruiting
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· Phase 3· NRG Oncology· Source
Active, not recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669· Phase 2· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error